The ErbB-1 receptor tyrosine kinase binds to six dierent growth factors, whose prototype is the epidermal growth factor (EGF). Two homologous epithelial receptors, ErbB-3 and ErbB-4, bind all isoforms of another family of growth factors, the Neu dierentiation factors (NDFs/neuregulins). The fourth member of the ErbB family, ErbB-2, acts as the preferred heterodimeric partner of ligand-occupied complexes of the three other ErbB proteins. Here we report that at high concentrations, EGF can induce cell growth and dierentiation in the absence of ErbB-1. This function is shared by betacellulin, but not by three other ligands, including the transforming growth factor a (TGFa). The functional receptor was identi®ed as a heterodimer between ErbB-3 and ErbB-2, a previously identi®ed oncogenic complex. When singly expressed, neither ErbB-3 nor ErbB-2 can mediate signaling by EGF. In addition, when co-expressed, blocking either receptor by using site-speci®c antibodies inhibited EGF and betacellulin activities, indicating strict cooperativity between ErbB-3 and ErbB-2. Through analysis of chimeras between EGF and TGFa, we identi®ed the middle portion of EGF (loop B) as the site that enables activation of ErbB-2/ErbB-3. In conclusion, cooperative and promiscuous binding of stroma-derived growth factors by the epithelium-expressed ErbB-2/ErbB-3 heterodimer may be signi®cant to cancer development. The mechanistic implications of our results for a model that attributes receptor dimerization to ligand bivalency, as well as to a recently proposed mechanism of secondary dimerization, are discussed.
Introduction
Transmembrane receptor tyrosine kinase (RTKs) regulate cell dierentiation or proliferation upon binding of the respective growth factors to the extracellular ligand binding sites (van der Geer et al., 1994) . Most RTKs belong to small groups of highly homologous receptors that bind similar ligands and maintain inter-receptor interactions through ligandinduced homo-and heterodimer formation (Heldin and Ostman, 1996) . One of the thoroughly investigated subfamilies of RTKs is the ErbB group (also called HER) (Alroy and Yarden, 1997) . The prototypic receptor of this subfamily, ErbB-1, binds six dierent mammalian ligands that share an epidermal growth factor-(EGF-) like motif (Groenen et al., 1994) , including EGF itself, transforming growth factor a (TGFa), amphiregulin (AR), betacellulin, heparinbinding EGF-like growth factor (HB-EGF), and epiregulin (Toyoda et al., 1995) . Two other receptors, ErbB-3 and ErbB-4, bind all isoforms of the Neu dierentiation factor (NDF, also called neuregulin) (Tzahar et al., 1994) . A fourth member of the family, ErbB-2, is an orphan receptor with no assigned ligand, that has been repeatedly implicated in cancer because its rodent mutant is highly tumorigenic (Bargmann et al., 1986) , and overexpression of the human wild-type protein is frequently associated with a signi®cant fraction of relatively virulent human adenocarcinomas (Stancovski et al., 1994) .
Despite the absence of a known ligand that binds directly to ErbB-2, this protein participates in an extensive network of ligand-induced formation of ErbB dimers. All ten possible dimeric complexes exist, but those containing ErbB-2, and especially the ErbB-2/ ErbB-3 heterodimers, are more stable and their signaling is more potent . Because in invertebrates, such as C. elegans and Drosophila, only one ErbB member is present (Kornfeld, 1997) , it is thought that gene duplication events expanded the mammalian ErbB network with the purpose of increasing diversity of signaling by EGF-like ligands. Indeed the diversi®cation potential of the ErbB family is enormous: Three layers of diversity can be de®ned at the ligand, receptor and eector levels. The four ErbB proteins are well suited for network function as they dier in many aspects, including their basal kinase activity and substrate speci®city. Remarkably, ErbB-3 carries a severely impaired catalytic function (Guy et al., 1994) . In addition, the four proteins dier in their cellular routing subsequent to ligand binding (Baulida et al., 1996) , and in their spatial and temporal expression patterns: whereas ErbB-2 is ubiquitously expressed in many types of mesenchymal, epithelial and neuronal cells, the expression of both types of NDF receptors is relatively limited. Because signaling downstream of each RTK depends on recruitment of a speci®c set of signaling proteins sharing phosphotyrosine-binding motifs (either SH2 or PTB), whose identity is determined by amino acid sequences surrounding receptor autophosphorylation sites (Son-gyang et al., 1993) , each ErbB dimer appears to couple to a distinct set of signaling molecules (Carraway and Cantley, 1994) .
Combinatorial interactions are not limited to the receptor and eector levels, but extend to the multiple ErbB ligands. It is clear that ErbB-1-speci®c ligands dier in their biological potency and anity (Kramer et al., 1994) , as do the two classes of NDF isoforms (Marikovsky et al., 1995) . In addition, betacellulin and HB-EGF, ligands that have been previously thought to interact only with ErbB-1, are also able to activate ErbB-4 (Riese et al., 1996a; Elenius et al., 1997) . It is quite possible that each of the multiple ErbB-1 ligands may be characterized by a distinct ability to recruit speci®c homo-and heterodimers of ErbB-1. This is indeed the case with NDF isoforms, whose b type is able to stabilize both ErbB-2/ErbB-3 and ErbB-1/ ErbB-3 heterodimers, whereas the lower anity a type cannot recruit the latter species (Pinkas-Kramarski et al., 1996a) . Ligand-speci®c heterodimer formation may be explained by a model that we have recently proposed. Accordingly, EGF-like ligands are bivalent; their high anity binding site recognizes a primary receptor, but a second site, whose anity is remarkably low, has a broad speci®city that allows dierential recruitment of a secondary receptor (Tzahar et al., 1997) .
Besides the role of the ErbB network in developmental processes (Burden and Yarden, 1997) , its function appears to be important for ®xation and propagation of oncogenic phenotypes in human epithelia. Autocrine and paracrine synthesis of the various ligands in the stroma underlying epithelial cell layers, and overexpression of members of the ErbB family, which is thought to bias formation of the respective dimers, contribute to an aggressive phenotype of adenocarcinomas, and in some cases correlate with poor prognosis (Salomon et al., 1995) . Amplification and overexpression of ErbB-2 have been reported for many carcinomas including breast, ovarian, lung, gastric and cervical carcinomas (Stancovski et al., 1994) , and correlated with poor prognosis of breast and ovarian cancer patient (Slamon et al., 1989) . Recent experiments using an endoplasmic reticulumtrapped single-chain antibody to ErbB-2, implied that this protein acts as a subunit of both EGF-and NDF-receptors (Graus-Porta et al., 1995; Karunagaran et al., 1996) . Accordingly, ErbB-2 prolongs and ampli®es signal transduction by several, if not all, types of EGF-like ligands by decelerating their rate of dissociation from the direct receptors. This activity is best exempli®ed by the ability of ErbB-2 to reconstitute an extremely high mitogenic activity of the kinase-defective ErbB-3 through formation of heterodimers (Pinkas-Kramarski et al., 1996b) . Unlike ErbB-3 homodimers, that are functionally inactive (Riese et al., 1995; Pinkas-Kramarski et al., 1996b) , ErbB-2/ErbB-3 heterodimers appear to be the predominant receptor of NDF in carcinoma cells . Consistent with the high stability and potent proliferative action of this complex, coexpression of ErbB-2 and ErbB-3 confers a transformed phenotype (Alimandi et al., 1995; Wallasch et al., 1995) , whose potency in ®broblasts is second only to an ErbB-1/ErbB-2 heterodimer (Cohen et al., 1996; Zhang et al., 1996) .
The emerging apparent promiscuity of some ErbB-1 ligands Riese et al., 1996a) , the possibility that ligand multiplicity is related to a bivalent model of ligand-receptor interactions (Tzahar et al., 1997) , and a recent observation that a limited structural change, namely replacement of only ®ve N-terminal amino acids, allowed EGF to bind to NDF-receptors (Barbacci et al., 1995) , prompted us to survey the ability of ErbB-1 ligands to act through an alternative receptor. By using a sensitive NDF-speci®c cell dierentiation assay, we identi®ed two ligands, EGF and betacellulin, that can use an ErbB-2/ErbB-3 heterodimer to mediate cellular eects in the absence of ErbB-1. Together with the observation that this heterodimer is endowed with an increased anity to NDF (Sliwkowski et al., 1994) , our results imply that ligand promiscuity may be a component that contributes to the oncogenic potential of this complementary receptor combination. Importantly, the ability of EGF to stimulate an ErbB-2/ErbB-3 heterodimer has been recently reported by another group, and led to the interpretation that secondary dimerization (ErbB-2/ErbB-3) follows dissociation of a primary ErbB-1-containing receptor dimer (Gamett et al., 1997 ). Because we demonstrate direct and cooperative interaction of EGF with the ErbB-2/ ErbB-3 heterodimer, our results favor an alternative to the secondary dimerization model.
Results
Induction of cellular dierentiation and tyrosine phosphorylation by EGF-like ligands in the absence of ErbB-1
Because an overexpressed ErbB-2 can enhance signaling by NDF and EGF (Graus-Porta et al., 1995; Karunagaran et al., 1996) and also elevates binding of these factors (Kokai et al., 1987; Sliwkowski et al., 1994) , we speculated that in the presence of an overexpressed ErbB-2, EGF or other direct ligands of ErbB-1, namely: TGFa, HB-EGF, AR, or betacellulin, may signal through an alternative receptor. This possibility was examined by using ErbB-2 overexpressing MDA-MB453 mammary tumor cells that express no ErbB-1, but can undergo phenotypic dierentiation in response to neuregulins, such as NDF/heregulin (Plowman et al., 1993) . A four day-long incubation with high concentrations of EGF or betacellulin, but not TGFa, led to a characteristic phenotype that included cell¯attening, growth arrest, up-regulation of the intercellular adhesion molecule 1 (ICAM-1), and appearance of neutral lipid-containing droplets ( Figure 1a ). Because NDF binding to ErbB-3 and to ErbB-4 elicited similar cellular alterations in breast cancer cells, we suspected that the major NDF receptor of epithelial cells, namely the ErbB-2/ErbB-3 heterodimer , was involved. Therefore, two ErbB-1 negative cell lines, that ectopically express a combination of the two receptors, were examined for induction of tyrosine phosphorylation. These are CB23 cells, a doubletransfected derivative of Chinese ovary (CHO) cells , and the D23 subline of the interleukin-3 (IL-3-) dependent 32D myeloid cell line (Pinkas-Kramarski et al., 1996b) . In both types of cells, as well as in MDA-MB453 cells, EGF and betacellulin, but not TGFa, HB-EGF or AR, increased tyrosine phosphorylation of a 180 kilodalton protein (Figure 1b) . However, by contrast with NDF, whose dierentiation and phosphorylation eects were detectable at 10 79 ± 10 78 M concentrations, the two ErbB-1 ligands displayed activity only when present at 5610 78 M or higher concentrations. The identity of the 180 kilodalton protein that underwent enhanced phosphorylation in response to EGF and betacellulin was examined by using antibodies speci®c to ErbB-2 or to ErbB-3. The results of this analysis indicated that the primary substrate of the EGF-and betacellulin-induced tyrosine phosphorylation was ErbB-3 ( Figure 1c) . Control experiments using a 32D cell derivative expressing ErbB-1 alone (D1 cells) excluded the possibility that the three non-functional ligands were misfolded or otherwise inactive, as these ligands induced high tyrosine phosphorylation of ErbB-1 (Figure 1b , and data not shown). The fact that amphiregulin was the least active ligand in the phosphorylation assay may be attributed to its relatively short C-tail, which was shown to confer weak binding and bioactivity (Adam et al., 1995) .
Co-expression of ErbB-2 and ErbB-3 allows EGF and betacellulin to induce proliferative signals
ErbB-expressing sublines of 32D cells strictly depend on the corresponding ErbB ligand for their growth (Pinkas-Kramarski et al., 1996b) , thereby providing a sensitive tool for comparing growth-regulatory signals by using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay (Mosman, 1983) . To test the prediction that EGF and betacellulin can mediate proliferative signals in 32D cells, D23 cells were deprived of IL-3 and incubated with various EGF-like ligands. As can be seen in Figure 2a both EGF and betacellulin, when added at relatively high concentrations, were able to induce cellular proliferation. Other ErbB-1 ligands were inactive on D23 cells, but they were mitogenic to various extents for D1 cells (Figure 2a ). Interestingly, unlike the relatively high mitogenic signals of EGF in D1 cells, this ligand was slightly inferior to betacellulin on D23 cells (Figure 2a) .
We next examined the long-term eect of ErbB-1 ligands on D23 and D1 cells in the absence of IL-3. Stimulation of the two 32D sublines with the various ligands revealed dierences which correlated with the relative short-term proliferative potential of each of the ligands. For example, TGFa and AR were the most and the least active ligands in both short-and long- Figure 1 Induction of cellular dierentiation and tyrosine phosphorylation by EGF-like ligands in the absence of the EGFreceptor. (a) MDA-MB453 human mammary cancer cells, that express no ErbB-1, were plated in chamber slides and then incubated for 4 days in the absence or presence of EGF (0.5 mg/ml). Cells were stained with either Oil red O, to visualize neutral lipids, or with an mAb to ICAM-1. Antibody visualization was performed by using a biotinylated rabbit anti-mouse IgG, followed by an alkaline phosphatase-conjugated streptavidin and a red chromogen. Note the appearance of lipid droplets (yellow) and ICAM-1 (red stain) in some, but not all, EGF-treated cells. The magni®cation used was 6600 (lipid staining) or 6400 (ICAM-1 staining). (b) Ligandinduced tyrosine phosphorylation was examined in the indicated cell lines by incubating 10 6 (MDA-MB453 and CB23 cells) or 10 7 (D1 and D23) cells without or with the following factors (0.5 mg/ml each) for 8 min at 378C: human EGF, TGFa, betacellulin, HB-EGF, AR, and NDF-b1 (EGF-like domain). Whole cell lysates were then prepared and immunoblotted (IB) with a mAb to phosphotyrosine (PY20). To identify proteins that underwent tyrosine phosphorylation, lysates prepared as in b were subjected to immunoprecipitation (IP) with the PY20 antibody to phosphotyrosine, and the washed immunocomplexes were resolved by electrophoresis and immunoblotting with either a rabbit antibody directed to ErbB-3, or mAb L87 to ErbB-2 (c). The protein bands detected with anti-ErbB-3 antibodies are all of the same molecular mass EGF-induced activation of ErbB-2/ErbB-3 R Pinkas-Kramarski et al term mitogenic assays of D1 cells, but both displayed no activity on D23 cells (Figures 2a and b) . Only EGF and betacellulin were able to support long-term survival of D23 cells. However, betacellulin was more eective than EGF as a survival factor for D23 cells ( Figure 2b ). As expected, neither EGF nor betacellulin elicited a proliferative response in 32D cells singly expressing ErbB-2 or ErbB-3, even when very high ligand concentrations were used (data not shown). Taken together, the results shown in Figure 2 indicated that both EGF and betacellulin, but not HB-EGF, TGFa and AR, can stimulate cell growth in the absence of ErbB-1 in cells co-expressing ErbB-2 and ErbB-3.
It is important to note that NDF exerted signi®cantly higher mitogentic ( Figure 2b ) and phosphorylation ( Figure 1b) eects than EGF or betacellulin, and it was active at much lower concentrations. These dierences raised the possibility that the interaction of the two ErbB-1 ligands with ErbB-2 and ErbB-3 was mediated by sites disparate from those that transmit NDF actions. To examine this proposition we used panels of monoclonal antibodies (mAbs) speci®c to each ErbB protein Klapper et al., 1997) . Two dierent types of mAbs to each receptor were used: antibodies that interfere with ligand binding and those that exert only a small eect on NDF binding. In the case of ErbB-3, mAb C105 belongs to the ®rst group, whereas C90 belongs to the second. The corresponding two classes of anti-ErbB-2 mAbs include, on the one hand, antibodies 26, 90, and 96, and, on the other hand, mAbs 87, 242 and 431. We have previously shown that the ®rst group of mAbs, but not the other class, accelerates dissociation of both EGF and NDF from ErbB-2-containing heterodimers . Co-culturing D23 cells with EGF or betacellulin in the presence of the various mAbs revealed that only mAbs that can directly interfere with NDF binding, signi®cantly inhibited EGF-and betacellulin-dependent proliferation of D23 cells. A summary of the results is given in Table 1 and the dependence of inhibition on antibody concentration is shown for two ligand-competitory mAbs in Figure 3 . Thus, the NDF-competitory mAb C105 , but not another mAb to ErbB-3 (Table 1) , completely abolished the proliferative eects of EGF and betacellulin. Likewise, all antagonist mAbs to ErbB-2, including mAb L96, inhibited EGF-and betacellulin-mediated eects on D23 cells in a dose-dependent manner (Figure 3 ). Due to the very high concentration of NDF used in the experiment presented in Figure 3 , only a partial blockade of its eect was observed with mAbs C105 and L96. In conclusion, both EGF and betacellulin interact with ErbB-2 and with ErbB-3 through sites that are immunologically indistinguishable from those recognized by NDF. Together with the lack of mitogenic eect on cells singly expressing either receptor, these results imply that in the absence of ErbB-1, both ErbB-2 and ErbB-3 are essential for the transmission of EGF and betacellulin actions.
Cooperative ligand binding to cells co-expressing ErbB-2 and ErbB-3
To directly test the necessity of both ErbB-2 and ErbB-3 for an EGF-induced mitogenic signal in the absence of ErbB-1, we examined their eects on ligand binding. First, we attempted to displace cell-bound radiolabeled NDF by using increasing concentrations of various ErbB-1 ligands. As predicted, both EGF and betacellulin, but not TGFa, were able to displace, in part, NDF from its binding sites on D23 cells ( Figure  4a ). Interestingly, when tested on a similar cell line that expresses ErbB-3 alone (D3 cells), only EGF was active (Figure 4a ), implying that ErbB-2 is more critical for betacellulin binding to the ErbB-2/ErbB-3 heterodimer than it is necessary for EGF recognition by the dimeric complex. However, it is important to note that D23 cells displayed an approximately tenfold higher anity to NDF than did D3 cells (Figure 4a ), in agreement with a previous report (Sliwkowski et al., 1994) . Therefore, the apparent similar ability of EGF to displace NDF from D3 and D23 cells (compare EGF displacement curves in the two panels of Figure 4a ) implies that ErbB-2 increases anity to EGF, as it does in the case of NDF and betacellulin.
Radiolabeling of the two ErbB-1 ligands enabled us to directly examine the necessity of the two receptors. Due to the relatively weak interactions and the ease of handling adherent cells, rather than cells growing in suspension (i.e. 32D derivatives), binding analyses were performed with transfected CHO cells expressing various ErbB proteins (CB cell series). By contrast to CHO cells expressing ErbB-1 alone (CB1 cells), which displayed moderate (K d =1 nM) and high (K d =0.2 nM) apparent anities to betacellulin and EGF, respectively, the two factors recognized CB23 cells with only low anity (K d =50 ± 80 nM) and ligand binding to cells singly expressing ErbB-2 or ErbB-3 was undetectable. To overcome the weak type of interactions we used the method of anity labeling, in which ligand dissociation is completely blocked by means of covalent crosslinking. When performed with D1 cells, EGF, betacellulin and TGFa labeled ErbB-1, but the two isoforms of NDF were inactive (Figure 4b ), consistent with high speci®city of the anity labeling method. Of the three ErbB-1 ligands, only EGF underwent weak covalent crosslinking to ErbB-3 in D3 cells, in agreement with the ability of this ligand to displace NDF from ErbB-3 expressing cells (Figure 4a ). Also in agreement with the ligand displacement assays, both EGF and betacellulin weakly labeled ErbB-3 in D23 cells, and both NDF isoforms displayed strong interactions with monomers and dimers of this receptor (Figure 4b ).
Mapping an EGF domain responsible for ErbB-2/ErbB-3 activation
Considering the highly related secondary and tertiary structures of EGF and TGFa (Moy et al., 1993; Jacobsen et al., 1996) , and the wealth of information available from site-directed mutagenesis of the two molecules (Groenen et al., 1994) , their dierential interaction with the ErbB-2/ErbB-3 complex prompted us to map the active domain of EGF. To this end we used a previously described (Kramer et al., 1994) series of chimeric molecules between EGF and L26  L90  L96  L242  L431  L87   7+4  0+4  7+1  44+2  70+3  64+3   10+3  0+2  11+3  57+1  83+3  74+3   C105  C90   0+1  100+3   0+2  97+1 D23 cells were preincubated for 1 h with mAbs (100 mg/ml) to either ErbB-2 (L series) or to erbB-3 (C series). The indicted growth factors were then added at a 500 ng/ml concentration. Cell proliferation was determined 24 h later, and expressed as percentage of the response to the same growth factor in the absence of antibody. The results represent the means+s.d. of six determinations Figure 3 Eect of monoclonal anti-receptor antibodies on ligand-induced proliferation of ErbB-2 and ErbB-3 co-expressing cells. 32D cells expressing both ErbB-2 and ErbB-3 (D23 cells) were preincubated for 1 h with serial dilutions of the indicated mAbs to either ErbB-3 (mAb C105) or to ErbB-2 (mAb L96). The following growth factors were then added, each at 0.5 mg/ml: EGF (open squares), betacellulin (closed circles) or NDF-b1 (open triangles). Cell proliferation was determined 24 h later as described in the legend to Figure 2a , and expressed relative to the signal obtained in the absence of mAbs. The results in both panels represent the means+s.d. of four determinations TGFa (Figure 5a ). Both mitogenic and kinasestimulatory activities of these mutants were tested with D23 cells. As shown in Figure 5 , a molecule comprised of the N-terminus of EGF (upstream to the third, out of six, cysteine) and the C-terminal half of TGFa (termed E3T) was inactive, but inclusion of an EGF sequence lying between the third and the fourth cysteine residues (loop B, E4T mutant) partially reconstituted both activities (Figures 5b and c) . Consistent with the possibility that the inter Cys3 ± Cys4 sequence was responsible for a signi®cant fraction of the biological activity of EGF, its replacement by the corresponding portion of TGFa (E3T4E mutant) abolished EGF activity, and its grafting into TGFa conferred to the mutant (termed T3E4T) slightly more than full activity. Taken together with the ability of EGF and betacellulin, but not other ErbB-1 ligands, to speci®cally activate cells through the combination of ErbB-2 with ErbB-3, the identi®cation of a discrete EGF domain as the active moiety implies that the interactions we described are highly speci®c.
Discussion
The unexpected ability of two ErbB-1-speci®c ligands to stimulate a heterodimer of ErbB-3 with ErbB-2 exhibits several speci®city features that imply physiological signi®cance: First, out of the ®ve mammalian EGF-like ligands we tested, only two interacted with the ErbB-2/ErbB-3 combination. In addition, each receptor alone was practically inactive in both phosphorylation and mitogenic functions, but their combination was cooperatively functional. Lastly, the coincidence of cooperativity with a relatively short linear sequence of EGF (Figure 5a) indicates highly speci®c recognition.
The mechanism by which a ligand promotes heterodimerization of its direct receptor with another ErbB protein is an interesting, but currently open, question. According to one model, that was supported by biophysical measurements of EGF interaction with a soluble ErbB-1 (Green®eld et al., 1989) , ligand binding is followed by a conformational alteration that exposes a cryptic dimerization site. An alternative model of ligand-induced receptor dimerization argues that EGF-like ligands are bivalent (Heldin and Ostman, 1996) . Studies performed with soluble ErbB-2 and ErbB-3 revealed that dimerization does not occur in solution (Horan et al., 1995; Tzahar et al., 1997) , thus weakening a conformation-based model. On the other hand, high resolution NMR studies of NDF/heregulin predicted the existence of two receptor binding sites (Jacobsen et al., 1996) . Indeed, our recent (10 6 ) were incubated for 2 h at 48C with a radiolabeled NDF-b1 (1 ng/ml) in the presence of increasing concentrations of an unlabeled NDF-b1 (triangles), EGF (open circles), betacellulin (closed circles) or TGFa (squares). To remove the unbound ligand, cells were sedimented (12 000 g, 2 min) through a cushion of calf serum at the end of the experiment, and their radioactivity determined. Non-speci®c binding of NDF was determined in the presence of 100-fold excess of the unlabeled ligand. Each data point represents the mean (less than 10% variation) of two determinations. (b) Covalent crosslinking of the indicated radioactive ligands (each at 250 ng/ml) was performed with 32D cells (10 7 cells per lane) singly expressing ErbB-1 (D1 cells) or ErbB-3 (D3 cells), or a combination of ErbB-2 with ErbB-3 (D23 cells). Following 1.5 h at 48C, the covalent crosslinking reagent BS 3 was added (1 mM) and cell lysates prepared after an additional 1.5 h of incubation at 48C. Anity-labeled ErbB-1, ErbB-2, or ErbB-3 were immunoprecipitated by using speci®c mAbs, that do not interfere with ligand binding, and the complexes resolved by gel electrophoresis and autoradiography. Arrows mark the locations of monomeric (M) and dimeric (D) receptor complexes studies indicate that the N-terminus of NDF recognizes ErbB-3, whereas the C-terminus of this ligand contains a second site whose anity is 1000-fold lower, but its ErbB speci®city is broader than that of the high anity site (Tzahar et al., 1997) . This bivalence model attributes formation of homo-and heterodimers to NDF isoform-speci®c selectivity of site 2 (Pinkas- Kramarski et al., 1996a) . Two recent studies support relevance of a similar bivalence model to EGF: First, anity labeling identi®ed two binding sites on ErbB-1, each located at the other side of the N-terminal cysteine-rich domain of this receptor, and interacts with one terminus of the ligand (Summer®eld et al., 1996) . Second, all possible stoichiometries of EGF : ErbB-1 were measured in solution, but the predominant ratio determined was 2 : 2 (Lemmon et al., 1997) . These studies join many previous lines of evidence supporting ligand bivalency, including immunological identi®cation of two non-overlapping regions within the EGF molecule as essential for receptor binding (Katsuura and Tanaka, 1989) , and de®nition of two binding sites in TGFa by using heptapeptides that encompass the whole sequence of this molecule (Richter et al., 1992) . In terms of a bivalent ligand, our results imply that EGF binds to ErbB-3 through its second loop (loop B, Figure 5) , one of the two regions whose involvement in receptor recognition was repeatedly indicated by mutagenesis. Speci®cally, mutagenesis identi®ed isoleucine 23 and leucine 26 of loop B as critical residues, but their eects were enhanced by interactions through the Cterminal tail (Campion et al., 1993) . Involvement of the latter domain emerged also from comparison of the binding of EGF and TGFa to the avian ErbB-1: An arginine 45 to alanine was identi®ed as a single replacement that conferred high anity receptor binding (van de Poll et al., 1995) . We, therefore, speculate that recruitment of ErbB-2 by EGF is mediated by the C-terminal tail, provided that ErbB-3 ®rst binds to EGF through loop B. Because the ®rst binding event is very weak, and direct binding to ErbB-2 may be even weaker (Horan et al., 1995; Tzahar et al., 1997) , heterodimerization of these two receptors by EGF is strictly cooperative.
Similar to the EGF-induced activation of an ErbB-2/ErbB-3 combination we observed in epithelial and in myeloid cells, a recent report described an analogous phenomenon in pheochromocytoma cells (PC12) (Gamett et al., 1997) . However, by using ErbB-speci®c tyrosine kinase inhibitors, and relatively high cell and ligand concentrations, these authors concluded that an ErbB-1/ErbB-2 heterodimer precedes formation of the secondary ErbB-2/ErbB-3 heterodimer. According to their model, an activated ErbB-2 is released by the transient primary heterodimer, and later activates ErbB-3. However, unlike PC12 cells, that express all of the three ErbB proteins, our transfected myeloid cells express only speci®c pairs of ErbB proteins (Pinkas-Kramarski et al., 1996b), a fact that allowed us to determine direct, but strictly cooperative, interaction of EGF with the ErbB-2/ErbB-3 heterodimer. Thus, our results are inconsistent with a model of secondary dimerization of ErbB proteins. Nevertheless, the observations made in PC12 cells exemplify the independence of EGF interaction with ErbB-2/ErbB-3 on a speci®c cell type, and its wide occurrence under experimental conditions.
We speculate that under several physiological conditions, EGF and betacellulin act as low anity ligands of the extremely potent ErbB-2/ErbB-3 heterodimer. For example, a few types of body¯uids, including saliva, urine and milk, may contain suciently high EGF concentrations to allow ErbB-1-independent signaling (Carpenter and Wahl, 1991) . Thus, EGF action through the ErbB-2/ErbB-3 complex may have an exocrine, rather than an endocrine, role. In addition, because both EGF and betacellulin are synthesized as transmembrane precursors, whose processing is regulated and tissue-speci®c (Massague and Pandiella, 1993) , immobilization by membrane anchorage, or alternatively, by extracellular matrix components, is expected to increase the operational anity of these low anity ligands in a juxtacrine type of interactions. Moreover, co-overexpression of ErbB-2 and ErbB-3 is another factor that is expected to promote binding at low ligand concentrations. This scenario is most relevant to human adenocarcinomas; ErbB-2 is frequently overexpressed in several types of human tumors, and its partner, ErbB-3, is almost ubiquitously present at moderate or high levels in these tumors (Lemoine et al., 1992) . On the other hand, the mesenchyme-derived stroma underlying epithelial cell layers, the precursors of adenocarcinomas, is a rich source of many ErbB ligands, including EGF and betacellulin (Salomon et al., 1995) . These, paracrine mesenchyme-epithel interactions, that mirror embryonic inductive processes (Birchmeier and Birchmeier, 1993) , are essential for tumor development (Salomon et al., 1995) . For example, overexpression of ErbB-2 is most frequently observed in comedo ductal carcinoma in situ (DCIS) (van de Vijver et al., 1987) , a noninvasive type of breast tumors surrounded by an integral mesenchyme-derived basement membrane. Because these tumors also express ErbB-3 at high levels, it is possible that the observed ligand promiscuity of the ErbB-2/ErbB-3 heterodimer confers to DCIS tumors, especially those lacking ErbB-1, a selective advantage. Beyond its potential evolutionary, mechanistic and physiological implications, our present study provides strong support to the emerging notion that the many ErbB-1-speci®c ligands are functionally distinct rather than redundant Riese et al., 1996b; Pinkas-Kramarski et al., 1996a) . Not only do these ligands dier in their expression, processing, and binding to accessory proteins through non-EGF-like domains, they also dier in receptor recognition. In fact, betacellulin emerges from this and a previous study (Riese et al., 1996a) as a pan-ErbB ligand, capable of activating all functional homo-and heterodimers, but the ErbB-2 and ErbB-3 homodimers. Additional experiments will have to address the speci®city of the other ErbB-1 ligands, and also possible interactions with ErbB-4-containing dimers. However, on the basis of our recent work with NDF isoforms (Pinkas-Kramarski et al., 1996a ) and the present results, it is already clear that the multiplicity of ErbB ligands constitutes an additional layer of diversi®cation to the ErbB signaling network. To which extent this enormous diversity is exhausted in vivo remains unclear (Alroy and Yarden, 1997) , but a series of gene targeting studies, culminating in ErbB-2 inactivation (Lee et al., 1995) , attributes biological relevance to at least part of this complexity.
Materials and methods

Materials, buers and antibodies
Recombinant forms of NDF (NDF-a2 177 ± 241 , or NDF-b1 177 ± 246 ) were from Amgen (Thousand Oaks, CA) . Human recombinant EGF, TGFa, HB-EGF, betacellulin and amphiregulin, were purchased from Sigma. Chimeric growth factors were puri®ed by using reverse-phase high pressure liquid chromatography with a linear gradient of acetonitrile in 0.1% tri¯uoroacetic acid. Fractions were tested in a displacement assay with radiolabeled EGF and ErbB-1-overexpressing cells. Peptide concentrations was determined on the basis of light absorption (229 nm) and compared with the results of EGF competition. The apparent anities to ErbB-1 of all chimeric proteins were comparable and in agreement with their concentrations. Polyclonal rabbit anti-ErbB-3 antibodies, and a monoclonal anti-phosphotyrosine antibody (PY-20) were purchased from Santa-Cruz Biotechnology (Santa-Cruz, CA). Binding buer contained RPMI medium with 0.5% bovine serum albumin. HNTG buer contained 20 mM HEPES (pH 7.5), 150 mM NaCl, 0.1% Triton X-100, and 10% glycerol. Solubilization buer contained 50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1% NP-40, 0.5% Na-deoxycholate, 0.1% sodium dodecyl sulfate (SDS), 1.5 mM EGTA, 1.5 mM MgCl 2 , 2 mM sodium orthovanadate, 1 mM phenylmethylsulfonyl¯uoride (PMSF), aprotinin (0.15 trypsin inhibitor unit/ml), and 10 mg/ml leupeptin.
Cell culture
A series of sublines derived from the 32D murine hematopoietic progenitor cell line and expressing various ErbB proteins has been previously described by us (PinkasKramarski et al., 1996b) . Cells were grown in RPMI-1640 medium supplemented with antibiotics, 10% heat-inactivated fetal bovine serum and 0.1% medium that was conditioned by the IL-3-producing X63/0 cells (Karasuyama and Melchers, 1988) . A parental 32D cell line that expresses no ErbB protein has been used in cell proliferation assays. No response to EGF-like ligands was observed with this control cell line. CB23, a CHO subline co-expressing ErbB-2 and ErbB-3 has been previously described . Cells were grown in DME medium supplemented with antibiotics and 10% heat inactivated bovine serum.
Ligand displacement and covalent crosslinking analyses
Recombinant ligands were labeled with iodogen (Pierce) as previously described . The speci®c activity ranged between 1 ± 5610 5 c.p.m./ng. Ligand binding analyses were performed with 10 6 suspension cells. Cells were washed once with binding buer, and then incubated for 2 h at 48C with the radiolabeled ligand (1 ng/ ml) and various concentrations of an unlabeled ligand, in a ®nal volume of 0.2 ml. To terminate ligand binding, each reaction tube was washed once with 0.5 ml binding buer and loaded on top of a 0.7 ml cushion of bovine serum. The tubes were spun (12 000 g, 2 min) in order to remove the unbound ligand and the radioactivity was determined by using a g-counter. Nonspeci®c binding was determined in the presence of an unlabeled NDF-b1 177 ± 246 at 10 76 M.
For crosslinking experiments, the various 32D cell lines (10 7 cells) were incubated on ice for 90 min with a radiolabeled ligand (200 ng/ml). The chemical crosslinking reagent bis(sulfosuccinimidyl) suberate (BS 3 ) was then added to 1 mM ®nal concentration, and after 1 h at 48C cells were washed with phosphate-buered saline. Cell lysates were prepared and analysed by immunoprecipitation and gel electrophoresis.
Cell proliferation assays
Cells were washed free of IL-3, resuspended in RPMI-1640 medium at 5610 5 cells/ml, and treated without or with growth factors at various concentrations for dose-response experiments. Cell survival was determined by using the MTT assay, which determines mitochondrial activity in living cells (Mosman, 1983) . MTT (0.1 mg/ml) was incubated with the analysed cells for 2 h at 378C. Living cells can transform the tetrazolium ring into dark blue formazan crystals, that can be quanti®ed by reading the optical density at 540 ± 630 nm after lysis of the cells with acidic isopropanol.
Lysate preparation and immunoprecipitation
Cells were exposed to the indicated stimuli in RPMI-1640 medium. After treatment, cells were pelleted by centrifugation and solubilized. Lysates were cleared by centrifugation (12 000 g, 10 min at cold). For direct electrophoretic analysis, boiling gel sample buer was added to cell lysates. For other experiments, lysates were ®rst subjected to immunoprecipitation with anti-phosphotyrosine antibodies (PY-20.5). Antibodies were ®rst coupled to rabbitanti-mouse immunoglobulin G and then to protein ASepharose by the same procedure. The proteins in the lysate supernatant were immunoprecipitated with aliquots of the protein A-Sepharose-antibody complex for 2 h at 48C. The immunoprecipitates were washed three times with HNTG, resolved by SDS-polyacrylamide gel electrophoresis through 7.5% acrylamide gels and electrophoretically transferred to nitrocellulose membranes. Membranes were blocked for 2 h in TBST buer (0.02 Tris HCl pH 7.5, 0.15 M NaCl and 0.05% Tween 20) containing 1% milk, blotted with 1 mg/ml primary antibody for 2 h, followed by 0.5 mg/ml secondary antibody linked to horseradish peroxidase. Immunoreactive bands were detected with an enhanced chemiluminescence reagent (Amersham Corp).
Immunocytochemistry
MDA-MB453 human mammary cancer cells were plated in chamber slides (Lab-Tek) and then incubated for 4 days in the absence or presence of EGF (500 ng/ml). Cells were stained with either Oil red O, to visualize neutral lipids, or with a mAb to ICAM-1 (Becton Dickinson) as previously described (Bacus et al., 1993) . Antibody visualization was performed by a second incubation with a biotinylated rabbit anti-mouse immunoglobulin G, followed by an alkaline phosphatase-conjugated streptavidin and a red chromogen (Advanced Cellular Diagnostics, Elmhurst, IL) .
